Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Thank you very much and welcome, everyone, to today's conference. Today we will first look into our performance in the third quarter and then also reflect a bit on the current market situation and our expectations for the remainder of 2025. So we can move over to page number two, please. So if we start by looking at the development of some of our long-term, more strategic KPIs, we can see that we continue to clearly track in line with our plan to increase the share of sales from recurring revenue products and also accelerate the share of sales from high-margin products like our Paragon offering or portfolio consumables in infection prevention and beta bags in sterile transfer. This is all supported by solid and effective quality processes as well. Sales from recurring revenue are now at 65%, and high margin products make up more than two-thirds of sales today. When it comes to quality, the number of field actions in relation to sales has decreased significantly, and we see this positive trend continuing. Also in the third quarter of this year, these improvements should, of course, be achieved through responsible leverage and an attractive long-term return on invested capital. We can move then to page number three please. So if we focus then on the third quarter for a moment and the key takeaways for the quarter, we can see that we demonstrated strength with significant growth in the topline. Net sales grew by 9.5% organically, with positive development in all business areas and all regions. Order intake also increased by 4.7% organically. Adjusted gross and EBITDA margins improved, mainly due to acquisitions. Healthy price increases, positive mix, and productivity gains. And this is in spite of continued strong headwinds from tariffs and currency impacts on the EBITA margin, which signals that the underlying development is even stronger. Our financial position remains solid, with our financial leverage well below two and a half times EBITA. We can then move over to page number four, please. So taking a step back then and looking at some of the key activities and events in the third quarter when it comes to our offering and customers, I'm happy to see that Sweden’s first fully automated, centralized sterile supply department at the Malmö University Hospital has been inaugurated, with Getinge’s T-DOC providing the intelligence that optimizes sterile supply management by enhancing quality, patient safety, cost efficiency, and also improving the work environment. T-DOC is really the critical enabler for successful operations, and this is something that we've seen for over 25 years now with this product. Productivity is a key priority for us. By implementing the Getinge Manufacturing Excellence Program, we've been able to cut lead times by more than 20% and also reduce the COGS by about 10% for some of our key products in the product category, which includes washers, isolators, and sterilizers. We've also joined forces with Philips to offer hospitals in key markets an integrated anesthesia workstation for the operating room. So this new solution unites precise anesthesia delivery and state-of-the-art patient monitoring technologies. Thank you very much and welcome, everyone, to today's conference. When it comes to sustainability and quality. In the quarter, we regained the CE Mark for our Cardiosave Intra-Aortic Balloon Pump. This is, of course, subject to certain conditions, and we plan to gradually resume deliveries towards the end of this year. Regarding our implants business, we received EU MDR approval for three additional indications for our V12 balloon expandable covered stents. And this will now strengthen our position. It's a critical enabler for success in the European endovascular market regarding our operations. Key Performance Indicators (KPIs). I'm happy to see that our CO2 emissions from operations continue to decrease. Let's move then to page number five and look at our top line performance in a bit more detail. Overall, we had a particularly strong top-line performance in acute care therapies and life sciences. Our order intake grew 4.7% organically, and the organic order intake for acute care therapies increased, mainly due to ventilators in critical care and ECLS consumables. Life Science showed double-digit growth in the organic order intake for the quarter due to very strong performance in style transfer, and the organic order intake for surgical workflows declined a bit in the quarter. Despite the strong trend that we've seen for operating tables and also consumables in infection control. When it comes to sales, we grew 9.5% organically. Both acute care therapies and life science saw double-digit growth in organic net sales. This was mainly due to the very strong performance in ventilator ECLS therapy and also within cardiac surgery. Organic net sales for life science primarily increased as a result of healthy growth in sterile transfer and also capital goods in the washer, isolator, and sterilizer category within surgical workflows. Organic net sales increased due to growth in infection control and also thanks to operating tables within surgical workflows. We can then move over to page number six and I'll hand over to you Agneta.
Thank you, Mattias. I will start on a positive note and highlight that despite some severe headwinds from tariffs and FX, we continue to see improvements throughout the business, leading to higher margins. Adjusted gross margin was up by 0.9 percentage points in total, primarily supported by pricing and a healthy mix. Looking at adjusted EBITDA, the positive effect from adjusted gross profit on the EBITDA margin was 1.4 percentage points. Thanks to what I just mentioned, adjusted for currency, operating expenses had a slight positive impact on the margin in the quarter. FX impacted negatively by -0.6 percentage points in the quarter. All in all, this resulted in an adjusted EBITDA of 1,079,000,000, improving our margin by about 1.6 percentage points year over year to 13.1%. We move to page seven, please. Let's have a closer look at the impact from tariffs. Earlier this year in our Q1 call, we shared some insights on our sales flows. So just to reiterate that about 60% of our sales in the US are produced in the US. For the EU and China respectively, About 10% is produced in the US, and about 1% of sales in the EU and US comes from China. As you know, the tariff discussions are highly dynamic, but this overview should provide a good understanding of our exposure in the third quarter. Costs of tariffs amounted to approximately -108 million SEK, adding the impact in Q2. We are then at -218 million SEK year to date. Let's move to page eight, please. So how are we then mitigating this? And what has been the impact on the margin? In our previous earnings call, we talked about the three main areas that we focus on to address this topic. And they are pricing, cost reduction, and reviewing and challenging our structural setup for sourcing and production. This is, of course, nothing new, but we have intensified the efforts in all three of these areas. The chart on the right illustrates the margin development year over year for Q3. First thing to note is the great comeback in adjusted EBITDA margin from 11.5% to 13.1% for the quarter. What the chart also illustrates with the blue line is what the margin would be without tariffs and with the turquoise line, what it would be with last year's currency rates. And at last year's currency rates. So without tariffs, we would have landed on a 14.4% margin. And when also neutralizing currency, we would have been at 14.9%. So this is a clear signal of our strong underlying performance and potential. Retention. Let's move to page nine and look at our financial situation. We remain in a solid financial position. Free cash flow amounted to 0.8 billion in the quarter, compared with last year. Free cash flow was positively impacted by improved operating profit and changes in working capital. Working capital days continue to develop well, and on operating return on invested capital, we improved to 12.5% on a rolling 12-month basis, which is well above the cost of capital at the end of Q3. Net debt was 11.1 billion. If we adjust liabilities, we are at 8.6 billion SEK. This brings us to a leverage of 1.6 times adjusted EBITDA, which is well below the 2.5 we have set as the internal threshold. If we adjust for pension liabilities, leverage is at 1.2 times adjusted EBITDA. Cash amounted to approximately 2.8 billion by the end of the quarter. So all in all, we can conclude that the financial position continues to be strong. Let's move to page ten, please. And back to you, Mattias.
All right. Thank you very much, Agneta. So, just moving then to our outlook for 2025. We will have a better balance between Q3 and Q4 this year. If you remember, last year we had a rather weak Q3 and a super strong Q4. And I think from an operations perspective, we will have a smoother second half of the year in 2025. So even though we're entering our fourth quarter with tough comparative figures, we believe that thanks to our leading position in key niches, we will meet the long-term increasing healthcare needs. Globally, we maintain our expectation for organic net sales growth to be in the range of 2 to 5%. Our long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency. So with that, we can move over to page 12, please, and just summarize the state of the unit after the third quarter here. So we've delivered strong organic growth with improved margins despite the significant headwind from tariffs and FX. Our financial position remains solid as just highlighted by Agneta Palmér. And we stick to our outlook for 2025, where we guide for organic net sales growth of 2 to 5%. And the priorities for 2025 are the same as they've been throughout the year, which means addressing the remaining challenges in acute care therapies when it comes to the important quality work. That is the number one priority for us. It's about sustainability, productivity improvements, and cost consciousness when navigating the current geopolitical uncertainty and, of course, addressing the impact from tariffs as well. Most importantly, we continue to create added value for our customers, which is demonstrated through the third quarter by our order intake growth and net sales growth. So with that summary, I open up for questions. And I think from an operations perspective, we will have a smoother second half of the year in 2025.
If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. The next question comes from Christopher Lilienberg from Carnegie. Please go ahead.
Yes. Hi. Good morning. My question relates to the strong ACT growth, and you highlighted ECMO. For example, is it possible to comment a bit more on that, maybe quantify how much the consumables are growing and in what markets? It is particularly interesting to hear if there's any change when it comes to the competitive dynamics in the US.
Yes. Good morning. Thank you. I think to address the latter part of the question first. There's no significant change when it comes to competitive dynamics. I think the strong growth in Act is, in addition to ECLS disposables, attributed to the growth in critical care and in cardiac surgery, which is also positive. The US is obviously one of the key markets that have been performing well in this regard, but we don't break down and disclose numbers for different product groups within the quarter.
But can you confirm that you experienced growth in ECMO consumables in the US?
Yes, we can.
Okay, good. And the same thing applies to sterile transfers within Life Science, are there specific drivers for that strong growth?
I think, generally, of course, the whole destocking is over. I think that's an important prerequisite. That's something we suffered from for a couple of years. And that's clearly been over for more than a year now. The other part is, of course, that there is a gradual comeback in the end market for these products. And I think in addition to this, one needs to be aware that this is a business that is also partly dictated by large contracts, and there's a certain lumpiness in the business between quarters, just to be aware of that also.
The US is obviously one of the key markets that have been performing well in this regard, but we don't break down and disclose numbers for different product groups within the quarter. And then the other question I had is if you could comment on the upcoming timing for filing the new Cardio Save and cardio health solutions in Europe.
In Europe, we've already received the CE Mark back for our Cardio Safe product. So, that's behind.
The new, updated version of Cardio Save and the new. So, the US is obviously one of the key markets that have been performing well in this regard, but we don't break down and disclose numbers for different product groups within the quarter.
So, the US is obviously one of the key markets that have been performing well in this regard, but we don't break down and disclose numbers for different product groups within the quarter. Yes. We've not provided any updated timeline on this. This is projected into 2026. So the first milestone is the 510(k) submission in the US for cardio. Say, that's the next milestone that we're working towards. And today, there is no update on the timeline.
So, the US is obviously one of the key markets that have been performing well in this regard, but we don't break down and disclose numbers for different product groups within the quarter.
So, the U.S. is obviously one of the key markets that has been performing well in this regard, but we don't break down and disclose numbers for different product groups within the quarter.
The next question comes from Mathias, from SEB. Please go ahead.
Yes. Good morning. Thank you for taking my questions. I was a bit curious to hear how it looks now with demand in ventilators during a good quarter. I think it's the fifth quarter in a row with very strong demand. So, could you describe a bit more in detail what you're hearing from customers? I am considering whether we should expect this trend to continue given the competitive dynamics. Or are comparisons increasingly tough going forward, which will slow it down a bit on a year-on-year basis? And, you know, anything that could help us here would be appreciated.
Yes, I think so. On both questions, we do expect this conversion to continue. There's been, as you probably are aware, a bit of an accelerated conversion of the installed base and a more prolonged conversion of the other two players' installed base. And that part, I think, will continue. But you're also right that we are meeting tougher comps now. I think the first positive developments were in Q3 last year, and then from Q4 onwards, we had very strong momentum when it comes to ventilator conversion in critical care.
Thank you. And then a follow-up on sterile transfer, looking very strong. Could you just describe a little bit where we are versus maybe peak volumes during COVID in this area. Now, are we higher than that, and maybe could you provide some comments specifically on beta bags? Also, you know, in terms of how they respond to the higher demand in sterile transfer.
Yeah, I think the beta bags definitely follow the high demand in sterile transfer. They're the biggest individual product within sterile transfer. Uh, for us. And, as you may remember, we had a 30% decline after Covid for two straight years. Uh, so we're not back at those levels, uh, yet, but, uh, it's a really encouraging comeback, I would say, where we stand right now.
Thank you very much. And then last one for me, perhaps, in terms of the tariffs, the impact was rather flat in Q3 compared to Q2. And then also, could you provide an outlook for the upcoming quarter? I don't know, but some comments here would be helpful. Yeah.
Yes, you are right. We managed to get some product into the U.S. before the raise of the tariffs from 10 to 15%, which were then delivered later in the quarter, so we did not have the full 15% impact in the third quarter. When it comes to what we have ahead, we will not speculate or provide guidance on future developments. This is a very dynamic situation, and there are many factors impacting it. And one of them is, of course, also the product mix.
Thank you.
The next question comes from Sten Gustafsson from ABG Sundal Collier. Please go ahead.
Good morning. A question, and it's related to page or slide eight where you show the margin development and what it would have been without tariffs and FX. How much of that improvement is driven by price, and how much is due to cost reduction and supply chain structure?
Yes. Thank you for that question. We will not break it down in detail, but price is an important contributor to the underlying performance, as are productivity improvements. So the main pieces are aligned with what we mentioned. It is mixed. We have contributions from our recent acquisition on the gross margin and also on the overall margin. In addition, we have factors such as pricing and productivity.
When it comes to what we have ahead, we will not speculate and not guide on. But would it be possible to get the information about how much you have raised your prices? No.
For reasons, we do not disclose the exact price increase.
But is it fair to assume that the majority of the increase comes from price?
Again, I will not break it down. It's also against that. But we know that we are fairly successful in price realization. When it comes to what we have ahead, we will not speculate and not provide guidance on that.
When it comes to what we have ahead, we will not speculate and not provide guidance.
And we've said earlier that we are aiming for price increases between 2 and 3% this year. And we are within that span. We won't break it down further.
No, that's very helpful. Thank you very much. My second question would be if you can talk about what kind of drivers you see for the gross margin in Q4 and also in terms of OpEx spending, if there are any things we should be mindful about going into Q4.
I think, firstly, just to repeat what Mattias Perjos just said, it's tough comps. When we come into Q4, we had a really strong delivery quarter last year. Some of what would normally be in Q3 was postponed into Q4 of 2024, which presents a tough comparison when it comes to the margin. We will not provide guidance on that. But as usual in Q4, we have a higher share of capital equipment deliveries that impact the gross margin, and for OpEx, it's the same situation. We will not give any specific guidance. But generally speaking, we have a seasonal pattern with some elevated costs in Q4 related to the higher volumes. And also to mention that from now, at the end of the third quarter and ahead, we have mix fully in our organic comparison as well.
And I think also beyond Q4, our main focus is on the underlying improvements that we're doing to our business for the longer term. Main focus is on the underlying improvements that we're making to our business for the longer term. Of course, they have factors like our manufacturing excellence that we mentioned for Life Science in the report, but there's still a lot of work to do when it comes to purchasing and other similar areas as well. So, we're optimistic that we can continue to improve our business, but you will have some swings between quarters that are important to keep in mind.
Thank you very much. Excellent. Thank you very much for your comments. Thank you.
The next question comes from Eric Castle from Danske Bank. Please go ahead.
Hi. Good morning. Not to beat a dead horse, but I want to talk about guidance. You only need to deliver roughly 1.7% organic growth in Q4 to get to the upper end. And, um, I guess the lower end is quite a daunting prospect. And yeah, sure, I guess that comps are a bit more challenging. You highlighted ventilators, for example, but can you help us pinpoint a bit more areas that you might be concerned about and as to why the upper limit is there to say? And do you still believe that the lower end is even on the table? And what would need to happen for you to get there?
Yeah, thanks for the question. I think we're not concerned about anything in particular in Q4. I think we have a well-functioning supply chain. We are mitigating tariffs and currency effects to the best of our ability. So, and I think the demand situation is fairly robust as well. So there's nothing that stands out as concerning. And we've not spent a lot of time narrowing the guidance span here. But obviously, if you look at the way things are tracking, you can work with different probabilities when it comes to the lower and higher end of the span, of course, but we have just not decided to invest a lot of time in that. Like in line with the previous question, we're a lot more focused, of course, on finishing the year, serving our customers the way they need and helping patients. And really focusing on the longer term, looking ahead to 2026 and beyond, in line with our guidance for 2027 and 2028, we feel that we are well underway towards achieving these goals.
I think we're not concerned about anything in particular in Q4. I think we're not concerned about anything in particular in Q4. That's fair enough. And then on Cardio Save. I know that the EU is a relatively small market, but what have you been seeing now for Cardio? Given that the CE Mark is back. Does there seem to be any sort of pent-up demand from customers that they're eager to order again, or is it fairly slow? And then also on Cardio Save, have you started to see any sort of change in use in the US after the guideline changes that happened earlier?
Yes. When it comes to the situation in the EU markets, we don't expect the resumption of deliveries to have any positive or material impact on the fourth quarter. But we can see from and hear from customers that there is pent-up demand. There are customers who would like to replace their existing balloon pumps. But it takes a while until we can actually have our factory focused on meeting demand for those customers. Therefore, there's no significant impact in Q4 for this regarding usage in the US. We've not seen any real change there either. We're trying to serve the customers with the consumables for the installed base while working on the 510(k) submission. That's really our key priority there. But there are no other changes from a market or customer perspective to highlight here.
Okay, good. A last question. You're reiterating long-term guidance again, essentially, and with both tariffs and FX being worse than at the Q2 report, reiterating the long term implies a sort of upgrade to the underlying performance that you see. And I guess if you agree with that, where have you found that sort of upside or rather, what sort of cushions might you have removed from the initial guidance now compared to Q2?
Yes, indeed. I mean, you're right, I think the underlying development is good at the moment. So that supports us reiterating the longer-term targets despite the slightly stronger headwinds from tariffs and currency. The main levers for this are those we've touched on before. I think pricing is one area where we're seeing good traction. There is still a lot of work for us to do when it comes to purchasing. Even though we have good material cost control, it doesn't mean that it can't get better. We're still, I think, only partly reaping the fruits from the hard work that was done to mitigate inflation during 2022 and 2023, so we still expect that to help as well. We have a positive mix rotation. Also, you can see this reflected in some of the longer-term strategic KPIs. And we now also have acquisitions that help towards this target. So those, I'd say, are the main factors for feeling confident despite the short-term headwinds.
All right. And I guess if you agree with that, where have you found that sort of upside or rather, what sort of cushions have you maybe removed from the initial guidance now compared to Q2? Thank you, Mattias. I'll jump back in queue.
The next question comes from Ludvig Lundgren from Nordea. Please go ahead.
And I guess if you agree with that, where have you found that sort of upside and or rather, what sort of cushions have you maybe removed from the initial guidance now compared to Q2?
Hello. Thank you for taking my questions. So two on Life Science, please. First, in Q1 you highlighted the slowdown due to or partly due to NIH budget constraints, and if some of this sales growth seen in Q3 is related to these projects, or is it other types of customers driving the sales growth in Q3?
It's very limited. I think the positive effect comes from the NIH comeback. I think there are still decisions pending to be made, both when it comes to NIH funding cuts specifically, but also regarding the general wait and see approach due to geopolitical uncertainty. So I think that's probably the bigger factor. So things have developed in a positive direction since Q1. But there's still some lingering uncertainty around these key projects, I'd say.
Okay, great. And then, the second one, just regarding the strong order intake you saw in the segment, which I assume is mainly related to capital equipment. Do you expect a Q4 budget flush similar to what we saw last year for the segment, or have you seen any other indications for this year? It's a figure of speech.
It's a good question, but very difficult to answer. We didn't expect any budget flush last year, but there certainly was some. So, fingers crossed for that this year as well. But it's too early to have any indication or view on this.
And then the second one, with the strong order intake you saw in the segment as well, which I assume is mainly related to capital equipment. Thank you very much.
And then the second one, just with the strong order intake you saw in the segment as well, which I assume is mainly related to capital equipment.
We have one anonymous caller. So could you please present yourself with your name and company? Please go ahead.
Hi. It's Ludwig from Handelsbanken here. Thanks for taking my questions. I have two, please. First one, just to get a bit more clarity on the tariff mitigations. In the report, you mentioned that you're successful with your price adjustment strategy, but in the short term, you need to absorb a large share of the tariff cost. And now, I believe you said that you still see a positive impact from price increases on your margins. Could you provide some clarity on what to expect going forward? How much more margin can we expect you to gain from price adjustments?
Yeah, I think the comment should be seen like this: when it comes to mitigating the specific tariffs that we pay, the price increases aren't aligned to fully compensate for those. So the price increase we are talking about is across the board, affecting all our products and all geographies. So in that sense, they do help. However, they're not specifically mitigating the tariffs on the product categories that are primarily exported to the US. So the 2 to 3% price improvement is a global figure. And the ones regarding specific product groups affected by tariffs. We don't disclose in detail, but that's where we're still absorbing some of this effect.
And then the second one, just so, with the strong order intake you saw in the segment as well, which I assume is mainly related to capital equipment. Thank you. And just a follow-up on the tariffs again, you mentioned you managed to do some shipping before the increased tariff rates. Can you give any comment on how close the 15% total hit from tariffs was over the entire quarter? Is it close to 15% or under 15?
No, we will not break it down like this. But it is. Still, if I put it like this, it did not impact the full 15%. It did not fully impact the two months as it would have if you normalized it over the quarter, perhaps. Yeah. A fairly big portion of what was sold in the third quarter. We managed to import before the rise of the tariffs. tiers.
And just a follow-up on the tariffs again, you mentioned you managed to do some shipping before the increased tariff rates. And just a follow-up on the tariffs again, you mentioned you managed to do some shipping before the increased tariff rates. And just a final question on quality, please. Could you provide any update around the 510(k) submission for balloon pumps in the US?
Yeah, there's no update on this. Right now. We're still working towards the end of this year and the second half of next year for the ECMO 510(K) submission.
All right. Thanks so much for taking the questions.
And just a follow-up on the tariffs again, you mentioned you managed to do some shipping before the increased tariff rates.
There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
All right. Thank you very much for participating in the discussion today. We've already made the summary here. And I just wish everybody a good rest of the day. And just a follow-up on the tariffs again, you mentioned you managed to do some shipping before the increased tariff rates.



















